Cytek Biosciences, Inc. (NASDAQ:CTKB) Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ET

Company Participants

Paul Goodson - Investor Relations
Wenbin Jiang - Chief Executive Officer
William McCombe - Chief Financial Officer

Conference Call Participants

Tejas Savant - Morgan Stanley

Brendan Smith - TD Cowen

Mason Carrico - Stephens

John Barnidge - Piper Sandler

Andrew Cooper - Raymond James

Operator

Thank you for standing by. At this time, I'd like to welcome everyone to the Cytek Biosciences' Third Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise.

After the speaker's remarks, there will be a question-and-answer session. [Operator Instructions] I will now turn the conference over to Paul Goodson, Investor Relations. Please go ahead.

Paul Goodson

Thank you, operator, earlier today, Cytek Biosciences released financial results for the quarter ended September 30, 2024. If you haven't received this news release, or if you'd like to be added to the company's distribution list, please send an email to investors@cytekbio.com.

Joining me today from Cytek are Wenbin Jiang CEO and CFO Bill McCombe. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of the federal securities laws, including statements regarding Cytek’s business plans, strategies, opportunities and financial projections.

These statements are based on the company's current expectations and inherently involve significant risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled Forward-Looking Statements in this press release Cytek issued today and in Cytek's filings with the SEC.

This call will include a discussion of certain financial measures that are not calculated in accordance with generally accepted accounting principles. Reconciliation to the most directly comparable GAAP financial measure may be found in today's earnings release submitted to the SEC.

Except as required by law, Cytek disclaims any duty to update any forward-looking statements, whether because of new information, future events or changes in its expectation. This conference call contains time sensitive information and is accurate only as of the live broadcast November 5, 2024.

Finally, I would like to announce that Cytek is hosting a full day user group meeting in Boston on December 5th. The meeting will feature presentations by users of our technology and Cytek scientists to share their research experience and ideas for how best to use Cytek's products. We have a limited amount of space for analysts and investors, so please let me know as soon as possible if you would like to attend.